Compare HFRO & CLPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HFRO | CLPT |
|---|---|---|
| Founded | 2000 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 406.7M | 467.9M |
| IPO Year | 2017 | 2009 |
| Metric | HFRO | CLPT |
|---|---|---|
| Price | $7.20 | $14.02 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | 91.8K | ★ 532.8K |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | ★ 8.87% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $36,971,000.00 |
| Revenue This Year | N/A | $45.67 |
| Revenue Next Year | N/A | $19.51 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 17.78 |
| 52 Week Low | $5.47 | $8.27 |
| 52 Week High | $7.74 | $30.10 |
| Indicator | HFRO | CLPT |
|---|---|---|
| Relative Strength Index (RSI) | 48.94 | 46.66 |
| Support Level | $6.94 | $12.30 |
| Resistance Level | $7.59 | $15.29 |
| Average True Range (ATR) | 0.19 | 0.61 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 32.05 | 35.79 |
Highland Opportunities and Income Fund is a non-diversified, closed-end management investment company. Its investment objective is to Income Fund seeks growth of capital along with income. It focuses on making investments in real estate securities, including Reits, secured and unsecured fixed-rate loans and corporate bonds, mezzanine securities, structured products, convertible and preferred securities and equities (public and private), and floating rate securities.
ClearPoint Neuro Inc is a commercial-stage medical device company that develops and commercializes integrated systems used in minimally invasive neurosurgical procedures in the brain. The company's business consists of two integrated components: a business providing medical devices for neurosurgical applications, and a business focused on partnerships in the biologics and drug delivery space. The Company operates in one reportable segment.